Fact Sheet

IQVIA Vigilance Detect for GLP-1 Therapies

AI-powered, scalable safety surveillance

The rapid expansion of GLP-1 therapies across approved, off-label, and accidental use has created a complex safety landscape. Marketing authorization holders now face high volumes of unstructured safety data, increased regulatory scrutiny, and operational inefficiencies in pharmacovigilance workflows.



Solution

IQVIA Vigilance Detect is a cloud-based pharmacovigilance platform that combines AI-driven automation with expert oversight to identify Adverse Events (AEs), Product Quality Complaints, and Off-Label use across diverse sources such as audio, email, chatbot logs, and scanned documents.

Key benefits: AI + safety expertise

- Powered by IQVIA AI Assistant, Vigilance Detect extracts safety-relevant data from structured and unstructured formats with speed and precision, outperforming traditional AI in upstream processing and enabling real-time signal detection.
- Reduces redundant data, improves intake quality, and boosts operational efficiency while ensuring compliance with evolving global safety regulations.

Flexible deployment

- Available as a self-managed solution or as a fully managed, end-to-end pharmacovigilance service through IQVIA.

System integration and compliance

- Supports multi-format, multi-language environments and integrates seamlessly with CRM, call center, and intake systems.
- Maintains GxP-compliant audit trails, MedDRA coding, and PII validation to meet regulatory standards.

AI Governance by design

- Built with transparent, explainable AI and aligned with global pharmacovigilance and AI regulations.
- Includes human-in-the-loop oversight and redress mechanisms for traceability and accountability.



Why leading companies choose Vigilance Detect: Real world impact

With 10+ years of experience, Vigilance Detect has monitored and reviewed over 100,000 audio calls, 25,000 source documents, 10,000 faxes, and 10,000 emails from patients/physicians discussing their experiences and results from being on GLP-1 products. Vigilance Detect has primarily monitored and reviewed GLP-1 safety data collected through Patient Support Programs.

Source document review

- Remediated **18,500** source documents.
- Identified **791** new AEs and **1,167** follow-ups not previously reported.

Patient adherence data analysis

- Analyzed **2** million records spanning five years.
- *Only* **1,500** records were deemed reportable, *significantly reducing* manual workload for commercial and drug safety teams.

Audio call surveillance

- Remediated **89,000** audio calls.
- Identified **7,608** new AEs and **8,395** follow-ups not previously reported to the global safety intake system.

Chatbot interaction monitoring

- Reviewed **350,000** chatbot records from patients inquiring about GLP-1 use prior to FDA approval.
- Identified **1,500** AEs and **3,500** weight loss-related events (off-label use).

Let's talk

Contact us or email vigilancedetect@iqvia.com to learn how we can assist your GLP-1 safety strategy.

IQVIA TECHNOLOGIES

CONTACT US
iqvia.com